K-BroVet 250: Product Information (Page 2 of 2)

References

1. Podell M, Fenner WR. Bromide therapy in refractory canine idiopathic epilepsy. J Vet Intern Med (1993) Sep-Oct. 7(5):318-27.

2. Trepanier, L.A. Use of bromide as an anticonvulsant for dogs with epilepsy. J Am Vet Med Assoc. 1995 Jul 15, 207(2) 163-6.

3. March PA, Podell M, Sams RA.Pharmacokinetics and toxicity of bromide following high-dose oral potassium bromide administration in healthy beagles. J Vet Pharmacol Ther 2002, 25:425-32.

4. Trepanier LA, Babish JG. Pharmacokinetic properties of bromide in dogs after intravenous and oral administration of single doses. Res Vet Sci 1995, 58 248-51.

5. Wolf RL., Eadie GS. Reabsorption of bromide by the kidney. AM S Physiol 1950. 163(2) 436-41.

6. USP Committee comment. Rec 9/9/04.

7. Palmer JW, Clarke HT. The elimination of bromides from the blood stream. J Biol Chem 1933; 99:435.

8. Yohn SE, Morrison WB, Sharp PE. Bromide toxicosis (bromism) in a dog treated with potassium bromide for refractory seizures. J AM Vet Med Assoc 1992 Aug 1, 201(13) 468-70.

9. Knight HD, Costner GC. Bromide intoxication of horses, goats and cattle. J Am Vet Med Assoc 1977 Sept 1; 171(5):446-8.

10. Pedersoli WM. Serum bromide concentrations during and after halothane anesthesia in dogs. Am J Vet Res 1980 Jan; 41(1) 77-80.

11. De Moor A, Van Den Hende C, Moens Y et al. Increased plasma bromide concentrations in the horse after halothane anesthesia. Am J Vet Res 1978 Oct. 39(10): 1624-6.

12. Gaskill CL, Cribb AE. Pancreatitis associated with potassium bromide/phenobarbital combination therapy in epileptic dogs. Can Vet L 2000 Jul, 4: 555-8.

13. Nichols ES, Trepanier LA, Linn K. Bromide toxicosis secondary to renal insufficiency in an epileptic dog. J Am Vet Med Assoc 1996 Jan 15, 208(2) 231-3.

14. Shaw N, Trepanier LA, Garland S. High dietary chloride content associated with loss of therapeutic serum bromide concentrations in an epileptic dog. J Am Vet Med Assoc 1996 Jan15.208 (2) 234-6.

15. Trepanier LA, Babish JG, Effect of dietary chloride content on the elimination of bromide by dogs. res vet Sci 1995; 58: 252-5.

16. Okuda K, Yasuhhara A, Kamei A, et al. Successful control with bromide of two patients with malignant migrating partial seizures in infancy. Brain Dev 2000 Jan; 22(1): 56-9

17. Ernst JP, Doose H, Baier WK. Bromides were effective in intractable epilepsy with generalized tonic-clonic seizures and onset in early childhood. Brain Dev 1988;10(6) 385-8.

18. Sisson A. Current experiences with anticonvulsants in dogs and cats. In: Proceedings of the fifteenth annual veterinary medical forum. Lakewood, Colorado: American College of Veterinary Internal Medicine 1997. p. 596-8.

19. Trepanier LA. Optimal bromide therapy and monitoring. In:Proceedings of the fifteenth annual veterinary medical forum. Lakewood, Colorado: American College of Veterinary Internal Medicine 1997. p. 100-101.

20. USP Committee comment, Rec 11/01/04.

21 Plumbs veterinary Handbook 6th Edition.

Principal Display Panel

PRN PHARMACAL

NDC #49427-322-48

K●BroVET® 250
Chewable Tablets

A liver flavored
chewable tablet
for dogs containing
Potassium Bromide

For additional product information
see supplemental fold-out booklet
on top of container.

NET CONTENTS 60 TABLETS

KBroVet 250mg Bottle Label
(click image for full-size original)
K-BROVET 250
potassium bromide tablet, chewable
Product Information
Product Type PRESCRIPTION ANIMAL DRUG Item Code (Source) NDC:49427-322
Route of Administration ORAL DEA Schedule
Active Ingredient/Active Moiety
Ingredient Name Basis of Strength Strength
POTASSIUM BROMIDE (BROMIDE ION) POTASSIUM BROMIDE 250 mg
Inactive Ingredients
Ingredient Name Strength
MICROCRYSTALLINE CELLULOSE 192.9 mg
DIBASIC CALCIUM PHOSPHATE DIHYDRATE 133 mg
CYANOCOBALAMIN 6.5 mg
STEARIC ACID 60.5 mg
Product Characteristics
Color brown (tan with brown speckles) Score 4 pieces
Shape ROUND (Cross Scored on one side imprint code on other side) Size 11mm
Flavor LIVER Imprint Code 250
Contains
Packaging
# Item Code Package Description Multilevel Packaging
1 NDC:49427-322-48 12 BOTTLE in 1 CARTON contains a BOTTLE
1 60 TABLET, CHEWABLE in 1 BOTTLE This package is contained within the CARTON (49427-322-48)
Marketing Information
Marketing Category Application Number or Monograph Citation Marketing Start Date Marketing End Date
unapproved drug other 02/23/2009
Labeler — Pegasus Laboratories, Inc. (108454760)
Establishment
Name Address ID/FEI Operations
Pegasus Laboratories, Inc. 108454760 manufacture, analysis, label
Establishment
Name Address ID/FEI Operations
BioSpectra 042724830 api manufacture

Revised: 12/2017 Pegasus Laboratories, Inc.

Page 2 of 2 1 2

VetLabel.com provides trustworthy package insert and label information about marketed drugs as submitted by manufacturers to the U.S. Food and Drug Administration. Package information is not reviewed or updated separately by VetLabel.com. Every individual animal healthcare product label entry contains a unique identifier which can be used to secure further details directly from the U.S. National Institutes of Health and/or the FDA.

Our database mirrors the FDA's central repository of drug labels and package inserts under the Structured Product Labeling standard. VetLabel.com provides the full animal health subset of the FDA's repository. Veterinary information provided here is not intended as a substitute for direct consultation with a qualified veterinary professional.

Terms of Use | Copyright © 2022. All Rights Reserved.